In the moderate stage of PD, patients begin to experience diminished benefit from antiparkinson medications. This phenomenon is often called narrowing of the therapeutic window. Motor fluctuations ...

One case–control study found that, compared with nonusers, patients treated with neuroleptics were roughly five times more likely to receive initial treatment with antiparkinson medications and ...